Interaction Checker

The content of the interaction checker was last updated in June 2022 and it is the responsibility of the user to assess the clinical relevance of the archived data and the risks and benefits of using such data.

Cookies help us deliver our services. By using our services, you agree to our use of cookies. Learn more
Start a new interaction query Switch to Normal View Results Key

Drug combinations may have been assessed either by study or within the product label, or an interaction may have been predicted based on the metabolic profiles of the drugs.

These drugs should not be coadministered

Potential clinically significant interaction that is likely to require additional monitoring, alteration of drug dosage or timing of administration.

Potential interaction likely to be of weak intensity. Additonal action/monitoring or dosage adjustment is unlikely to be required

No clinically significant interaction expected

There are no clear data, actual or theoretical, to indicate whether an interaction will occur

Generate a personalised report in PDF format

Do Not Coadminister

Potential Interaction

Potential Weak Interaction

No Interaction Expected

No Clear Data

Capecitabine Rituximab
Capecitabine
Everolimus (Immunosuppressant)
Famotidine
Ipratropium bromide
Nadroparin
Omeprazole
Oxycodone
Paracetamol (Acetaminophen)
Perazine
Rituximab
ARCHIVE SUPPORT